Acumen Pharmaceuticals to Present at Bank of America Health Care Conference
Event summary
- Acumen Pharmaceuticals will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026.
- The event will be webcast live and archived for 90 days.
- Acumen is developing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease.
- The company is conducting a Phase 2 clinical trial (ALTITUDE-AD) for early symptomatic Alzheimer’s patients.
- Acumen is also exploring a subcutaneous formulation of sabirnetug using Halozyme’s ENHANZE® technology.
The big picture
Acumen Pharmaceuticals’ participation in the Bank of America Securities 2026 Health Care Conference underscores its focus on advancing sabirnetug through clinical trials. The company’s strategic partnerships with Halozyme and JCR Pharmaceuticals highlight its efforts to enhance drug delivery and brain penetration technologies. As the biopharmaceutical industry continues to prioritize innovative Alzheimer’s treatments, Acumen’s progress in targeting toxic soluble amyloid beta oligomers could position it as a key player in the space.
What we're watching
- Clinical Progress
- How the Phase 2 ALTITUDE-AD trial results will impact Acumen’s valuation and investor confidence.
- Strategic Partnerships
- Whether collaborations with Halozyme and JCR Pharmaceuticals will accelerate sabirnetug’s development timeline.
- Market Positioning
- The pace at which Acumen can differentiate itself in the competitive Alzheimer’s disease treatment landscape.
Related topics